FDA picks Eli Lilly and Regeneron for a program to speed up domestic drug factory reviews
The FDA estimates the PreCheck program could save participating companies up to 14 months by reviewing facilities while they are still under construction
Overview
The FDA estimates the PreCheck program could save participating companies up to 14 months by reviewing facilities while they are still under construction
Source
Originally published at qz.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
